MedTrace Logo

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-01-14

No results posted yet for this study

Summary

This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.

Conditions

Interventions

DRUG

TD-1473

oral capsule/tablet, QD

DRUG

Itraconazole

oral solution, QD

Sponsors & Collaborators

  • Theravance Biopharma

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Theravance Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2018-07-15
Completion
2018-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03555617 on ClinicalTrials.gov